Ventyx Biosciences (VTYX) Proxy Filing summary

Executive summary

• A special meeting is called for shareholders to vote on a proposed merger with Eli Lilly and Company, where each share of common stock will be converted into $14.00 in cash, representing a 62% premium over the 30-day average trading price prior to the announcement.

• The board unanimously recommends voting in favor of the merger, the related executive compensation, and the right to adjourn the meeting if more votes are needed.

• If approved, Ventyx will become a wholly owned subsidiary of Eli Lilly, and its shares will be delisted from Nasdaq.

Voting matters and shareholder proposals

• Shareholders are asked to vote on: (1) adoption of the merger agreement, (2) approval, on a non-binding advisory basis, of compensation payable to named executive officers in connection with the merger, and (3) adjournment of the meeting if necessary to solicit more votes.

• The board recommends voting FOR all proposals.

• Appraisal rights are available for shareholders who do not vote in favor and follow the required procedures.

Board of directors and corporate governance

• The board conducted a strategic review, engaged with multiple potential acquirers, and determined the Lilly offer was the best available.

• All directors and officers entered into support agreements to vote their shares in favor of the merger.

• The board considered the fairness of the offer, the process, and the lack of superior alternatives.